Ultragenyx CEO talks the company’s path to profitability in developing drugs for rare diseases
Dr. Emil Kakkis, Ultragenyx founder & CEO, joins ‘Closing Bell Overtime’ to talk drug trials and development, its path to profitability and more.
Similar Posts
Cramer’s Mad Dash: Chewy
CNBC’s Jim Cramer delivers his daily Mad Dash.
The biggest mistake the Fed can make is to cut rates too quickly, says IBM’s Gary Cohn
Gary Cohn, IBM vice chairman, joins ‘Money Movers’ to discuss the CPI report and the Fed’s next move.
Investors are missing out on valuable parts of the stock market, says Mayflower’s Larry Glazer
Investors: It’s time to ditch the barbells. So says Larry Glazer, managing partner at Mayflower Advisors, who argued in a Tuesday interview on CNBC’s “Futures Now” that barbell investing — a strategy that involves buying into low-risk, stable assets as well as riskier speculative investments — is putting U.S. investors in an “extreme and dangerous”…
RapidRatings’ James Gellert: Boeing declines in financial health rating
ShareShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email The Exchange James Gellert, RapidRatings executive chair, joins ‘The Exchange’ to discuss the financial health of Boeing, shipping companies, and more. 03:24 2 hours ago
China seems to think that it is ‘out of the woods’: Professor
ShareShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email Edmund Phelps of Columbia University says China seems to think that it has solved its problems, and its economy will see a return to “somewhat higher” growth rates. He also says China could “break loose” with a long wave of rapid innovation….
Fmr. SEC Chair Jay Clayton: The dynamics of bitcoin trading are better understood and disclosed
ShareShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email Former SEC Chairman Jay Clayton joins ‘Squawk on the Street’ to discuss the latest on the bitcoin ETF approval decision, fallout from the SEC hack, and more.
